Withdrawn application: Dyrupeg, pegfilgrastim, Date of withdrawal: 08/06/2023, Initial authorisation
CuraTeQ Biologics s.r.o. withdrew its application for a marketing authorisation of Dyrupeg for use in cancer patients to reduce the duration of neutropenia (low levels of neutrophils, a type of white blood cell) and prevent febrile neutropenia (neutropenia accompanied by fever due to an infection). Neutropenia is a common side effect of cancer chemotherapy and can leave patients vulnerable to infections.
The company withdrew the application on 8 June 2023.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
